Systemic JAK Inhibitors for Vitiligo: Emerging Clinical Trial Data and Safety Considerations

Segment summary: In this episode titled "Systemic JAK Inhibitors for Vitiligo: Emerging Clinical Trial Data and Safety Considerations," moderator Nada Elbuluk, MD, MSc, FAAD and panelist Susan Taylor, MD, FAAD review the emerging pipeline of oral JAK inhibitors for vitiligo and discuss the safety considerations relevant to this therapeutic class.

Dr. Elbuluk introduces several systemic JAK inhibitors currently in clinical development — including upadacitinib, povorcitinib, ritlecitinib, and baricitinib — none of which are yet FDA-approved for vitiligo, though many have completed or are ongoing in Phase 3 trials. She highlights upadacitinib as particularly timely, having presented new data at the AAD meeting earlier that year.

Dr. Taylor reviews data for upadacitinib at the 15 mg dose, reporting that at 48 weeks, approximately 25% of treated patients achieved meaningful improvement in the facial VASI score compared to approximately 6% in the placebo group; for total body VASI, response rates were approximately 20% versus 6%. She emphasizes that results improved with longer duration of treatment, and that treatment-emergent adverse events were similar to the topical agent — primarily respiratory tract infection, acne, nasopharyngitis, and headache — with no reported venous thrombosis, MACE, or malignancy.

The discussion then covers baricitinib in combination with narrowband UVB phototherapy, which yielded approximately 45% total body VASI response compared to roughly 10% in the phototherapy-alone placebo group, reinforcing the synergy between JAK inhibition and light-based therapy. Povorcitinib and ritlecitinib are also reviewed, with both showing superiority over placebo in repigmentation endpoints and similarly manageable adverse event profiles.

Dr. Elbuluk emphasizes the importance of the favorable safety signals observed across all systemic JAK inhibitors in vitiligo — noting the absence of thromboembolic events, MACE, and malignancy. Dr. Taylor adds that individualized risk assessment — accounting for age, cardiovascular risk factors, smoking history, prior thromboembolic disease, and history of malignancy — remains essential when considering systemic therapy, regardless of the overall reassuring safety profile.

In the next episode, "The Future of Vitiligo Care: Patient Selection, Treatment Access, and the Road Ahead," the panelists discuss when to consider systemic JAK inhibitors, how to individualize therapy based on patient risk profiles, and the critical need for improved access to emerging vitiligo treatments.

This video series is not sponsored, and has been produce independently by Dermatology Times.